Treating Neurogenic Lower Urinary Tract Dysfunction in Chronic Spinal Cord Injury Patients—When Intravesical Botox Injection or Urethral Botox Injection Are Indicated

Po Cheng Chen; Kau Han Lee; Wei Chia Lee; Ting Chun Yeh; Yuh Chen Kuo; Bing Juin Chiang; Chun Hou Liao; En Meng; Yao Lin Kao; Yung Chin Lee; Hann Chorng Kuo

doi:10.3390/toxins15040288

Treating Neurogenic Lower Urinary Tract Dysfunction in Chronic Spinal Cord Injury Patients—When Intravesical Botox Injection or Urethral Botox Injection Are Indicated

Po Cheng Chen, Kau Han Lee, Wei Chia Lee, Ting Chun Yeh, Yuh Chen Kuo, Bing Juin Chiang, Chun Hou Liao, En Meng, Yao Lin Kao, Yung Chin Lee, Hann Chorng Kuo

Department of Urology(NCKUH)

Research output: Contribution to journal › Review article › peer-review

8 Citations (Scopus)

Abstract

Lower urinary tract symptoms (LUTS), such as urgency, urinary incontinence, and/or difficulty voiding, hamper the quality of life (QoL) of patients with spinal cord injury (SCI). If not managed adequately, urological complications, such as urinary tract infection or renal function deterioration, may further deteriorate the patient’s QoL. Botulinum toxin A (BoNT-A) injection within the detrusor muscle or urethral sphincter yields satisfactory therapeutic effects for treating urinary incontinence or facilitating efficient voiding; however, adverse effects inevitably follow its therapeutic efficacy. It is important to weigh the merits and demerits of BoNT-A injection for LUTS and provide an optimal management strategy for SCI patients. This paper summarizes different aspects of the application of BoNT-A injection for lower urinary tract dysfunctions in SCI patients and provides an overview of the benefits and drawbacks of this treatment.

Original language	English
Article number	288
Journal	Toxins
Volume	15
Issue number	4
DOIs	https://doi.org/10.3390/toxins15040288
Publication status	Published - 2023 Apr

All Science Journal Classification (ASJC) codes

Toxicology
Health, Toxicology and Mutagenesis

Access to Document

10.3390/toxins15040288

Cite this

Chen, P. C., Lee, K. H., Lee, W. C., Yeh, T. C., Kuo, Y. C., Chiang, B. J., Liao, C. H., Meng, E., Kao, Y. L., Lee, Y. C., & Kuo, H. C. (2023). Treating Neurogenic Lower Urinary Tract Dysfunction in Chronic Spinal Cord Injury Patients—When Intravesical Botox Injection or Urethral Botox Injection Are Indicated. Toxins, 15(4), Article 288. https://doi.org/10.3390/toxins15040288

@article{0700c4e917c4437abb87ab04feafae93,

title = "Treating Neurogenic Lower Urinary Tract Dysfunction in Chronic Spinal Cord Injury Patients—When Intravesical Botox Injection or Urethral Botox Injection Are Indicated",

abstract = "Lower urinary tract symptoms (LUTS), such as urgency, urinary incontinence, and/or difficulty voiding, hamper the quality of life (QoL) of patients with spinal cord injury (SCI). If not managed adequately, urological complications, such as urinary tract infection or renal function deterioration, may further deteriorate the patient{\textquoteright}s QoL. Botulinum toxin A (BoNT-A) injection within the detrusor muscle or urethral sphincter yields satisfactory therapeutic effects for treating urinary incontinence or facilitating efficient voiding; however, adverse effects inevitably follow its therapeutic efficacy. It is important to weigh the merits and demerits of BoNT-A injection for LUTS and provide an optimal management strategy for SCI patients. This paper summarizes different aspects of the application of BoNT-A injection for lower urinary tract dysfunctions in SCI patients and provides an overview of the benefits and drawbacks of this treatment.",

author = "Chen, {Po Cheng} and Lee, {Kau Han} and Lee, {Wei Chia} and Yeh, {Ting Chun} and Kuo, {Yuh Chen} and Chiang, {Bing Juin} and Liao, {Chun Hou} and En Meng and Kao, {Yao Lin} and Lee, {Yung Chin} and Kuo, {Hann Chorng}",

note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = apr,

doi = "10.3390/toxins15040288",

language = "English",

volume = "15",

journal = "Toxins",

issn = "2072-6651",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "4",

}

TY - JOUR

T1 - Treating Neurogenic Lower Urinary Tract Dysfunction in Chronic Spinal Cord Injury Patients—When Intravesical Botox Injection or Urethral Botox Injection Are Indicated

AU - Chen, Po Cheng

AU - Lee, Kau Han

AU - Lee, Wei Chia

AU - Yeh, Ting Chun

AU - Kuo, Yuh Chen

AU - Chiang, Bing Juin

AU - Liao, Chun Hou

AU - Meng, En

AU - Kao, Yao Lin

AU - Lee, Yung Chin

AU - Kuo, Hann Chorng

PY - 2023/4

Y1 - 2023/4

N2 - Lower urinary tract symptoms (LUTS), such as urgency, urinary incontinence, and/or difficulty voiding, hamper the quality of life (QoL) of patients with spinal cord injury (SCI). If not managed adequately, urological complications, such as urinary tract infection or renal function deterioration, may further deteriorate the patient’s QoL. Botulinum toxin A (BoNT-A) injection within the detrusor muscle or urethral sphincter yields satisfactory therapeutic effects for treating urinary incontinence or facilitating efficient voiding; however, adverse effects inevitably follow its therapeutic efficacy. It is important to weigh the merits and demerits of BoNT-A injection for LUTS and provide an optimal management strategy for SCI patients. This paper summarizes different aspects of the application of BoNT-A injection for lower urinary tract dysfunctions in SCI patients and provides an overview of the benefits and drawbacks of this treatment.

AB - Lower urinary tract symptoms (LUTS), such as urgency, urinary incontinence, and/or difficulty voiding, hamper the quality of life (QoL) of patients with spinal cord injury (SCI). If not managed adequately, urological complications, such as urinary tract infection or renal function deterioration, may further deteriorate the patient’s QoL. Botulinum toxin A (BoNT-A) injection within the detrusor muscle or urethral sphincter yields satisfactory therapeutic effects for treating urinary incontinence or facilitating efficient voiding; however, adverse effects inevitably follow its therapeutic efficacy. It is important to weigh the merits and demerits of BoNT-A injection for LUTS and provide an optimal management strategy for SCI patients. This paper summarizes different aspects of the application of BoNT-A injection for lower urinary tract dysfunctions in SCI patients and provides an overview of the benefits and drawbacks of this treatment.

UR - http://www.scopus.com/inward/record.url?scp=85154047950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85154047950&partnerID=8YFLogxK

U2 - 10.3390/toxins15040288

DO - 10.3390/toxins15040288

M3 - Review article

C2 - 37104226

AN - SCOPUS:85154047950

SN - 2072-6651

VL - 15

JO - Toxins

JF - Toxins

IS - 4

M1 - 288

ER -

Treating Neurogenic Lower Urinary Tract Dysfunction in Chronic Spinal Cord Injury Patients—When Intravesical Botox Injection or Urethral Botox Injection Are Indicated

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this